Doug Frandsen Email

Corporate Controller . Emalex.

Current Roles

Employees:
22
Revenue:
$3.4M
About
Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.
Emalex. Address
330 N. Wabash
Chicago, IL
United States
Emalex. Email

Past Companies

Emalex BiosciencesCorporate Controller
Orphazyme A/SU.S. Controller
TakedaAssociate Director, Controller's Group

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.